The drug targets the overgrowth of synovial cells and inflammatory components that drive tumor development and joint ...

Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discovering, developing, and commercializing important ...

BioWorld Content on 'tenosynovial giant cell tumors'Synox Therapeutics Ltd. has raised $75 million in a series B round to fund phase III development of emactuzumab, an antibody in-licensed from Roche ...

Source Reference: Gelderblom H, et al "Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial" Lancet ...

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical ...

TURALIO is the first and only oral systemic therapy approved in the U.S. for adult patients with tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and ...

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT).

Tenosynovial giant cell tumor (TGCT) is a rare, benign and locally aggressive disease that originates in the synovial lining of joints, bursae, and tendon sheaths, leading to thickening and ...

Global Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT) met the primary endpoint, demonstrating objective response rate at week 25 of 54.0% versus 3.2% for placebo (p ...

Vimseltinib is the first and only therapy with a positive CHMP opinion for the treatment of TGCT in the European Union Deciphera Pharmaceuticals, LLC, a biopharmaceutical company focused on discoverin ...